Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Gkotzamanidou M, Terpos E, Bamia C, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL.

Leukemia. 2014 May;28(5):1113-21. doi: 10.1038/leu.2013.284. Epub 2013 Oct 3.

PMID:
24089038
2.

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Gkotzamanidou M, Sfikakis PP, Kyrtopoulos SA, Bamia C, Dimopoulos MA, Souliotis VL.

Br J Cancer. 2014 Sep 23;111(7):1293-304. doi: 10.1038/bjc.2014.410. Epub 2014 Jul 22.

3.

Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.

Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP.

DNA Repair (Amst). 2006 Aug 13;5(8):972-85. Epub 2006 Jun 15.

PMID:
16781199
4.
5.

Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.

Kloth JK, Hillengass J, Listl K, Kilk K, Hielscher T, Landgren O, Delorme S, Goldschmidt H, Kauczor HU, Weber MA.

Int J Cancer. 2014 Nov 15;135(10):2380-6. doi: 10.1002/ijc.28877. Epub 2014 Apr 17.

6.

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.

Paiva B, Pérez-Andrés M, Vídriales MB, Almeida J, de las Heras N, Mateos MV, López-Corral L, Gutiérrez NC, Blanco J, Oriol A, Hernández MT, de Arriba F, de Coca AG, Terol MJ, de la Rubia J, González Y, Martín A, Sureda A, Schmidt-Hieber M, Schmitz A, Johnsen HE, Lahuerta JJ, Bladé J, San-Miguel JF, Orfao A; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas); Myeloma Stem Cell Network (MSCNET).

Leukemia. 2011 Apr;25(4):697-706. doi: 10.1038/leu.2010.320. Epub 2011 Jan 21.

PMID:
21252988
7.

A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.

Scudla V, Ordeltova M, Bacovsky J, Vytrasova M, Sumna E, Martinek A, Horak P.

Neoplasma. 2003;50(5):363-71.

PMID:
14628090
8.

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Pérez-Persona E, Vidriales MB, Mateo G, García-Sanz R, Mateos MV, de Coca AG, Galende J, Martín-Nuñez G, Alonso JM, de Las Heras N, Hernández JM, Martín A, López-Berges C, Orfao A, San Miguel JF.

Blood. 2007 Oct 1;110(7):2586-92. Epub 2007 Jun 18.

9.

Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.

Andersen NF, Kristensen IB, Preiss BS, Christensen JH, Abildgaard N.

Eur J Haematol. 2015 Sep;95(3):211-7. doi: 10.1111/ejh.12473. Epub 2015 Jan 7.

PMID:
25353275
10.

Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.

Dong L, Chen CY, Ning B, Xu DL, Gao JH, Wang LL, Yan SY, Cheng S.

Genet Mol Res. 2015 Aug 14;14(3):9571-84. doi: 10.4238/2015.August.14.20.

11.

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, Greipp PR, Rajkumar SV.

Blood. 2004 Aug 15;104(4):1159-65. Epub 2004 May 6.

12.

Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.

Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F.

Blood. 1999 May 1;93(9):3064-73.

13.

Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Waxman AJ, Kuehl M, Balakumaran A, Weiss B, Landgren O.

Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):248-57. doi: 10.3816/CLML.2010.n.053. Review.

PMID:
20709660
14.

The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.

Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL.

Eur Radiol. 2014 Nov;24(11):2754-65. doi: 10.1007/s00330-014-3324-5. Epub 2014 Aug 9.

PMID:
25106487
15.

Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.

Hillengass J, Moehler T, Hundemer M.

Recent Results Cancer Res. 2011;183:113-31. doi: 10.1007/978-3-540-85772-3_6. Review.

PMID:
21509683
16.

Myelomagenesis: capturing early microenvironment changes.

Korde N, Maric I.

Semin Hematol. 2011 Jan;48(1):13-21. doi: 10.1053/j.seminhematol.2010.11.004. Review.

17.

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.

Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR.

Clin Cancer Res. 2002 Jul;8(7):2210-6.

18.

Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E.

J Clin Oncol. 2002 Mar 15;20(6):1625-34.

PMID:
11896113
19.

MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).

Xiao R, Cerny J, Devitt K, Dresser K, Nath R, Ramanathan M, Rodig SJ, Chen BJ, Woda BA, Yu H.

Am J Surg Pathol. 2014 Jun;38(6):776-83. doi: 10.1097/PAS.0000000000000213.

PMID:
24705315
20.

Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Balakumaran A, Robey PG, Fedarko N, Landgren O.

Expert Rev Mol Diagn. 2010 May;10(4):465-80. doi: 10.1586/erm.10.31. Review.

Supplemental Content

Support Center